Details

Autor(en) / Beteiligte

• Tanaka, Ken-Ichiro
• Kurotsu, Shota
• Asano, Teita
• Yamakawa, Naoki
• Kobayashi, Daisuke
• Yamashita, Yasunobu
• Yamazaki, Hiroshi
• Ishihara, Tomoaki
• Watanabe, Hiroshi
• Maruyama, Toru
• Suzuki, Hidekazu
• Mizushima, Tohru

Titel

Superiority of pulmonary administration of mepenzolate bromide over other routes as treatment for chronic obstructive pulmonary disease

Ist Teil von

• Scientific reports, 2014-03, Vol.4 (1), p.4510, Article 4510

Ort / Verlag

England: Nature Publishing Group

Erscheinungsjahr

2014

Link zum Volltext

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• We recently proposed that mepenzolate bromide (mepenzolate) would be therapeutically effective against chronic obstructive pulmonary disease (COPD) due to its both anti-inflammatory and bronchodilatory activities. In this study, we examined the benefits and adverse effects associated with different routes of mepenzolate administration in mice. Oral administration of mepenzolate caused not only bronchodilation but also decreased the severity of elastase-induced pulmonary emphysema; however, compared with the intratracheal route of administration, about 5000 times higher dose was required to achieve this effect. Intravenously or intrarectally administered mepenzolate also showed these pharmacological effects. The intratracheal route of mepenzolate administration, but not other routes, resulted in protective effects against elastase-induced pulmonary damage and bronchodilation at a much lower dose than that which affected defecation and heart rate. These results suggest that the pulmonary route of mepenzolate administration may be superior to other routes (oral, intravenous or intrarectal) to treat COPD patients.